Literature DB >> 1905317

The influence of inadvertent intranasal buserelin administration in early pregnancy.

J Smitz1, M Camus, P Devroey, N Bollen, H Tournaye, A C Van Steirteghem.   

Abstract

Buserelin was inadvertently administered during 13 early pregnancies in 12 women with long-standing infertility, who had started the GnRH-agonist for gonadotrophin desensitization prior to ovarian stimulation for IVF. Six women delivered a healthy child and one pregnancy continues uneventfully. Three patients aborted before the sixth week and three women with tubal disease had an ectopic pregnancy. Corpus luteum function was normal in 11 of the 13 pregnancies. Although no evidence of embryotoxic effects of buserelin was observed, barrier contraceptive methods should be advised during the first days of its administration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1905317     DOI: 10.1093/oxfordjournals.humrep.a137324

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  3 in total

1.  Outcome of pregnancies inadvertently exposed to gonadotropin-releasing hormone analogues (GnRH-a) in early gestation.

Authors:  Y Gonen; M Dirnfeld; H Abramovici
Journal:  J Assist Reprod Genet       Date:  1993-08       Impact factor: 3.412

2.  Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist as the Only Luteal Support-Results of a Prospective, Randomized, Comparative Study.

Authors:  Céline Pirard; Ernest Loumaye; Pascale Laurent; Christine Wyns
Journal:  Int J Endocrinol       Date:  2015-04-05       Impact factor: 3.257

3.  No significant long-term complications from inadvertent exposure to gonadotropin-releasing hormone agonist during early pregnancy in mothers and offspring: a retrospective analysis.

Authors:  Huan Wu; Xiaoyan Xu; Cong Ma; Yiran Zhou; Shanai Pei; Hao Geng; Ye He; Qianhua Xu; Yuping Xu; Xiaojin He; Ping Zhou; Zhaolian Wei; Xiaofeng Xu; Yunxia Cao
Journal:  Reprod Biol Endocrinol       Date:  2021-03-20       Impact factor: 5.211

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.